Next Investors logo grey

YPB to service TGA approved PT Combiphar


Published 10-SEP-2019 08:49 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Product authentication and consumer engagement solutions provider YPB Group Limited (ASX:YPB) has signed a new three year Master Supply Agreement (MSA) with leading Indonesian pharmaceutical and wellness company PT Combiphar.

Combiphar has been an important YPB client since September 2016 and the leading user of YPB’s ProtectCodeTM product authentication solution, indicating that this is very much an endorsement of the group’s products and quality of service.

The new MSA allows for the extension of product coverage from the present to others in Combiphar’s 170 SKU product portfolio, potentially resulting in increased revenues from the client.

The new MSA anticipates broader product coverage and given the planned SKUs, volumes and pricing under the new MSA, YPB expects revenues over its three year life to be circa $1 million based on:

  • continued application of ProtectCodesTMon Combiphar’s cough syrup;
  • increased volumes from broader SKU coverage; and
  • new YPB Connect SaaS platform and support fees.

YPB and Combiphar are presently developing plans for the rollout of coverage to further products, and management will inform the market when these are activated.

Explaining how this latest development fits with the company’s revitalised strategy, YPB Group chief executive John Houston said, “Our refreshed strategy has health products as a key vertical market of focus and we are delighted to extend and expand our close collaboration with Combiphar.

‘’We anticipate our solutions enhancing Combiphar’s engagement with greater numbers of its consumers by assuring the authenticity of a broader range of its products.”

Slower uptake, but gaining traction

YPB first informed the market of its relationship with Combiphar in September 2016

In an announcement to the ASX, the company said that it expected revenues of $1 million over the 3 year life of that agreement.

YPB noted today that only around half that revenue originally anticipated was achieved due to a slow initial take-up of the solution in the first 18 months, and only one product line has been covered so far.

However, it appears that the company is a much larger organisation today, and it also benefits from strong affiliations with multinational Pharma companies such as GlaxoSmithKline (GSK), Sanofi and Abbott.

Combiphar produces more than 170 product lines across the prescription and over-the-counter segments including OBH Combi cough syrup, Insto eye-care solution and JointFit gel-based relief for joints.

It also acts as a contract manufacturer for global pharm giants including GlaxoSmithKline (GSK), Sanofi and Abbott, and has obtained Therapeutic Goods Administration (TGA) certification to allow the export of certain products to Australia.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.